Source: NioCorp Developments.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NioCorp Developments has demonstrated the potential to double titanium recovery from each tonne of ore at its Nebraska-based Elk Creek Critical Minerals Project
  • The company’s new recovery process achieved an 83.7 per cent rate of overall titanium recovery, compared to the previous rate of 40.3 per cent
  • The new process is expected to produce a purer form of titanium, known as titanium tetrachloride (TiCl4), which commands a higher market price than synthetic rutile
  • NioCorp Developments (TSX:NB) opened today at $7.01

NioCorp, a critical minerals stock, has demonstrated the potential to double titanium recovery at its Elk Creek Critical Minerals Project.

The company’s new recovery process, tested at a demonstration plant in Quebec, achieved an 83.7 per cent rate of overall titanium recovery, compared to the previous rate of 40.3 per cent.

The new process is expected to yield a purer form of titanium, known as titanium tetrachloride (TiCl4), which commands a higher market price than synthetic rutile. TiCl4 is used in the production of high-purity titanium oxides and compounds, primarily in the manufacturing of white pigments, titanium metal, and aerospace-grade titanium alloys.

The demand for titanium metal and alloys has been rising, and the United States heavily relies on foreign nations for its titanium supply. NioCorp’s improved process could help address this supply chain risk by offering a more reliable and domestic source of titanium.

The company sees opportunities to become a key supplier of titanium to industries important to U.S. national defense and commercial markets.

NioCorp plans to conduct further work, including updating mineral reserves, engineering studies, and cost estimates, before finalizing its titanium production plans.

NioCorp Developments is a mineral development company focused on critical minerals.

NioCorp Developments (TSX:NB) opened today at $7.01.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Herald
Neuralink - Founder, Elon Musk.

" Neuralink brain chips approved for human trials

Elon Musk’s Neuralink, a brain implant firm, has received regulatory approval for U.S. human trials.

" @ the Bell: TSX snaps three-day losing skid

After a series of sessions in the red, Canada’s main stock index closed out Friday trading in the green as commodity prices nudged

" Marvell stock spikes 30 per cent on Q1 news  

Marvell Technology (NASDAQ:MRVL) shares rose more than 30 per cent Friday.